JP2020505350A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505350A5 JP2020505350A5 JP2019538484A JP2019538484A JP2020505350A5 JP 2020505350 A5 JP2020505350 A5 JP 2020505350A5 JP 2019538484 A JP2019538484 A JP 2019538484A JP 2019538484 A JP2019538484 A JP 2019538484A JP 2020505350 A5 JP2020505350 A5 JP 2020505350A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- combination according
- acid sequence
- constant region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762448460P | 2017-01-20 | 2017-01-20 | |
| US62/448,460 | 2017-01-20 | ||
| PCT/IB2018/050348 WO2018134782A1 (en) | 2017-01-20 | 2018-01-19 | Combination therapy for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020505350A JP2020505350A (ja) | 2020-02-20 |
| JP2020505350A5 true JP2020505350A5 (enExample) | 2021-02-25 |
Family
ID=61168137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019538484A Ceased JP2020505350A (ja) | 2017-01-20 | 2018-01-19 | 癌の治療のための組合せ療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220356222A9 (enExample) |
| EP (1) | EP3570869A1 (enExample) |
| JP (1) | JP2020505350A (enExample) |
| KR (1) | KR20190105584A (enExample) |
| CN (1) | CN110177568A (enExample) |
| AU (2) | AU2018208883B2 (enExample) |
| CA (1) | CA3046120A1 (enExample) |
| IL (1) | IL266993A (enExample) |
| RU (1) | RU2019122408A (enExample) |
| WO (1) | WO2018134782A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| TW202028226A (zh) * | 2018-12-13 | 2020-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | Ｉｌ－１５蛋白複合物聯合ｐｄ－ｌ１抗體用於治療腫瘤疾病的用途 |
| CN116574183A (zh) * | 2019-08-22 | 2023-08-11 | 盛禾(中国)生物制药有限公司 | 多功能抗体、其制备及其用途 |
| CR20220367A (es) * | 2020-02-05 | 2022-08-30 | Novartis Ag | Célula cho que expresa heterodímeros il-15 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL71691A (en) | 1984-04-27 | 1991-04-15 | Yeda Res & Dev | Production of interferon-ypsilon |
| US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
| TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
| US6569681B1 (en) | 2000-03-14 | 2003-05-27 | Transkaryotic Therapies, Inc. | Methods of improving homologous recombination |
| EP3263581B2 (en) | 2005-05-17 | 2025-07-09 | University of Connecticut | Compositions and methods for immunomodulation in an organism |
| WO2007070488A2 (en) | 2005-12-12 | 2007-06-21 | The Cbr Institute For Biomedical Research, Inc. | Integrin alpha l i domain mutants with increased binding affinity |
| MX357691B (es) | 2006-01-13 | 2018-07-19 | The Government Of The United States As Represented By The Secretary Of The Department Of Health And | Il-15 y il-15r-alfa mejoradas para expresion en celulas mamiferas. |
| ES2642008T3 (es) | 2007-05-11 | 2017-11-14 | Altor Bioscience Corporation | Moléculas de fusión y variantes de IL-15 |
| EP2326531B2 (en) | 2008-08-22 | 2021-01-13 | Magna Seating Inc. | Disc recliner with reduced backlash |
| EP3851459B1 (en) | 2010-09-21 | 2024-05-01 | Altor BioScience, LLC | Multimeric il-15 soluble fusion molecules and methods of making and using same |
| EP2911684B1 (en) * | 2012-10-24 | 2019-06-19 | Novartis Ag | Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes |
| ES2716685T3 (es) | 2014-01-24 | 2019-06-14 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo para PD-1 y usos de las mismas |
| KR102762243B1 (ko) * | 2014-06-30 | 2025-02-05 | 알토 바이오사이언스 엘엘씨 | Il-15-베이즈드 분자 및 이의 사용 방법 |
| UY36351A (es) * | 2014-10-14 | 2016-06-01 | Novartis Ag | Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas |
-
2018
- 2018-01-19 JP JP2019538484A patent/JP2020505350A/ja not_active Ceased
- 2018-01-19 WO PCT/IB2018/050348 patent/WO2018134782A1/en not_active Ceased
- 2018-01-19 CA CA3046120A patent/CA3046120A1/en active Pending
- 2018-01-19 KR KR1020197020516A patent/KR20190105584A/ko not_active Ceased
- 2018-01-19 US US16/479,089 patent/US20220356222A9/en not_active Abandoned
- 2018-01-19 RU RU2019122408A patent/RU2019122408A/ru unknown
- 2018-01-19 CN CN201880007116.4A patent/CN110177568A/zh active Pending
- 2018-01-19 AU AU2018208883A patent/AU2018208883B2/en not_active Ceased
- 2018-01-19 EP EP18703630.6A patent/EP3570869A1/en not_active Withdrawn
-
2019
- 2019-05-29 IL IL266993A patent/IL266993A/en unknown
-
2021
- 2021-05-04 AU AU2021202787A patent/AU2021202787A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102412023B1 (ko) | 레날리도마이드 또는 포말리도마이드 및 ｃｄ38 항체-감쇠 인터페론-알파 구성체의 조합, 및 이의 용도 | |
| JP2024150751A5 (enExample) | ||
| JP6647208B2 (ja) | 抗ｉｌ−１７抗体、その生産および使用のための方法 | |
| JP2017529838A5 (enExample) | ||
| RU2017120358A (ru) | Анти-il-1-бета антитела и способы их применения | |
| JP2017160208A5 (enExample) | ||
| JP2018505177A5 (enExample) | ||
| JP2020511947A5 (enExample) | ||
| JP2014114288A5 (enExample) | ||
| JP2017534646A5 (enExample) | ||
| JP2018522540A5 (enExample) | ||
| JP2020505350A5 (enExample) | ||
| JP2010520290A5 (enExample) | ||
| JP2019517540A5 (enExample) | ||
| JP2017534645A5 (enExample) | ||
| CN110612309A (zh) | 用于降低免疫原性的方法和组合物 | |
| JP2020527152A5 (enExample) | ||
| JP2020502219A5 (enExample) | ||
| JP2018529661A5 (enExample) | ||
| JP2019532970A5 (enExample) | ||
| RU2019122408A (ru) | Средство комбинированной терапии для лечения рака | |
| JP2017524675A5 (enExample) | ||
| TW202104274A (zh) | 用於治療ｈｉｖ感染之三特異性及／或三價結合蛋白 | |
| JPWO2022053655A5 (enExample) | ||
| JPWO2022053654A5 (enExample) |